John Melish, MD
Internal Medicine · Honolulu, HINPI 1205868361
Payments from drug & device makers
Across 20 payments — averaging $97.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$564
- Corcept Therapeutics$379
- Mannkind Corporation$250
- Sanofi-aventis U.S. LLC$163
- Novo Nordisk$152
- Insulet Corporation$141
- plus $300 from 3 others
What the payments were for
- Food & beverage$1,87396%
- Education$754%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 4 | $564 |
| Corcept Therapeutics | 4 | $379 |
| Mannkind Corporation | 3 | $250 |
| Sanofi-aventis U.S. LLC | 2 | $163 |
| Novo Nordisk | 2 | $152 |
| Insulet Corporation | 1 | $141 |
| Bayer | 1 | $130 |
| Dexcom, Inc. | 2 | $128 |
| Lilly USA, LLC | 1 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,948 in reported general payments places this provider in the 75th percentile of 655 internal medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 15 | $22,724 |
| Humalog Kwikpen U-100Insulin Lispro | 36 | $7,312 |
| Praluent PenAlirocumab | 13 | $6,337 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $5,137 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $3,638 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 24 | $2,588 |
| Hydrocortisone | 11 | $754 |
| SynthroidLevothyroxine Sodium | 19 | $568 |
| Metformin Hcl | 55 | $515 |
| Simvastatin | 23 | $437 |
| Lisinopril | 20 | $271 |
| Levothyroxine Sodium | 43 | $244 |
| Losartan Potassium | 11 | $179 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Honolulu
- Keith WooHonolulu$106K
- Ronald PerryHonolulu$102K
- Laurie TomHonolulu$95K
- Yusuke MiyataniHonolulu$80K
- Joshua TanHonolulu$76K
- Jose de LeonHonolulu$52K
- Peter DeeHonolulu$49K
- James LumengHonolulu$45K
- Charles ZerezHonolulu$44K
- Anthony HernandezHonolulu$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.